SLS-005 contains the active ingredient trehalose, a low molecular weight disaccharide (0.342 kDa) that has been shown to penetrate muscle and cross the blood brain barrier. The Food and Drug ...

DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole. “SCAs [spinocerebellar ataxias] are, ...

Neurodegenerative disorders like Alzheimer’s and Parkinson’s disease result from the loss of specific types of neurons due to abnormal accumulation of mutant proteins. Although specific brain regions ...

The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

NEW HAVEN, Conn., May 23, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) today announced top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of ...

(BPT) – A rare disease is a disease, disorder, illness or condition that affects fewer than 200,000 Americans. 1 Since rare diseases impact a small number of people, they often remain relatively ...

(RTTNews) - Biohaven Ltd. (BHVN) announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed the company that they have extended the PDUFA date for the troriluzole new drug ...

Researchers have confirmed a link between altered DNA repair and increased DNA damage associated with spinocerebellar ataxia type 7 (SCA7), a debilitating, sometimes deadly neurodegenerative condition ...

A team led by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, along with Professor Yoshitaka Nagai at Kindai University, conducted a ...

European Commission approves OMP Designation for NLX-112 (befiradol) following compelling results in studies funded by the US Dept of Defense. This OMP designation is a milestone for Neurolixis as we ...